Chin-Sang Chung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chin-Sang Chung has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Mi Ji Lee
Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
15 shared publicationsHyun Ah Choi
Department of Neurology, Neuroscience Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
10 shared publications- Mi Ji Lee
Correspondence: Mi Ji Lee, M.D., Ph.D. Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, 03080 Seoul, Republic of Korea Tel: +82-2-2072-3925, Fax: +82-2-3672-7553
9 shared publications Hanna Choi
Department of Neurology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, Korea
7 shared publicationsSoohyun Cho
Department of Neurology, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Gyeonggi, South Korea
6 shared publications- Min Kyung Chu
Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
5 shared publications
Latest Publications
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Clinical Neurology
- Vol. 20 (1) , 86-93
An Analysis of the Determinants of the Health-Related Quality of Life in Asian Patients With Cluster Headaches During Cluster Periods Using the Time Trade-Off Method
Kim SK, et al. J Clin Neurol. 2024 Jan;20(1):86-93. https://doi.org/10.3988/jcn.2022.0396
- 1 January 2024
- Published by XMLink in Journal of Clinical Neurology
- Vol. 20 (1) , 86-93
Open AccessAn Analysis of the Determinants of the Health-Related Quality of Life in Asian Patients With Cluster Headaches During Cluster Periods Using the Time Trade-Off Method
Kim SK, et al. J Clin Neurol. 2024 Jan;20(1):86-93. https://doi.org/10.3988/jcn.2022.0396
- Open Access
- 31 March 2022
- Published by Sungkyunkwan University School of Medicine in Precision and Future Medicine
- Vol. 6 (1) , 2-8
The under-recognized but essential role of the limbic system in the migraine brain: a narrative review
Migraine is a very common brain disorder that causes throbbing headaches of moderate-to-severe intensity that are associated with a variety of symptoms like nausea, vomiting, multisensory hypersensitivity, dizziness, fatigue, cognitive dysfunction, and sleep problems, among others. The diverse symptomatology of migraine hints at the complexity of the disease and implies the involvement of multiple nervous system components, including the somatosensory, executive, autonomic, endocrine, and arousal networks. The major pathophysiologic mechanisms responsible for migraine attacks have been identified over the past several decades, and the elucidation of these mechanisms has brought about remarkable advances in therapeutic strategies, including the creation of anti-calcitonin gene-related peptide therapeutics—the newest addition to the list of anti-migraine therapies. However, current knowledge on the pathophysiologic mechanisms of migraine remains incomplete and treatments are only partially effective, with the involvement of the limbic system being less often recognized and symptoms related to the limbic system being undertreated. This article reviews recent advances in understanding the pathophysiologic roles of the limbic system in migraine and how the limbic system contributes to clinical features observed in migraine.
- 31 March 2022
- Published by Sungkyunkwan University School of Medicine in Precision and Future Medicine
- Vol. 6 (1) , 2-8
Open AccessThe under-recognized but essential role of the limbic system in the migraine brain: a narrative review
Migraine is a very common brain disorder that causes throbbing headaches of moderate-to-severe intensity that are associated with a variety of symptoms like nausea, vomiting, multisensory hypersensitivity, dizziness, fatigue, cognitive dysfunction, and sleep problems, among others. The diverse symptomatology of migraine hints at the complexity of the disease and implies the involvement of multiple nervous system components, including the somatosensory, executive, autonomic, endocrine, and arousal networks. The major pathophysiologic mechanisms responsible for migraine attacks have been identified over the past several decades, and the elucidation of these mechanisms has brought about remarkable advances in therapeutic strategies, including the creation of anti-calcitonin gene-related peptide therapeutics—the newest addition to the list of anti-migraine therapies. However, current knowledge on the pathophysiologic mechanisms of migraine remains incomplete and treatments are only partially effective, with the involvement of the limbic system being less often recognized and symptoms related to the limbic system being undertreated. This article reviews recent advances in understanding the pathophysiologic roles of the limbic system in migraine and how the limbic system contributes to clinical features observed in migraine.
- Open Access
- 8 April 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-8
RCVS–TCH score can predict reversible cerebral vasoconstriction syndrome in patients with thunderclap headache
Reversible cerebral vasoconstriction syndrome (RCVS) is one of the most important differential diagnosis in patients with thunderclap headache (TCH). We aimed to develop a new scoring system for RCVS in patients with TCH. We retrospectively analyzed 72 patients enrolled in the prospective study of TCH conducted in 2015–2016 (derivation set). We identified possible predictors for the diagnosis of RCVS and constructed a prediction model (RCVS–TCH score) using the multivariable logistic regression model. Diagnostic performance was validated to an independent validation set from our headache registry. The derivation set comprised 41 patients with RCVS and 31 with non-RCVS, and the validation set included 253 patients with TCH (165 with RCVS and 88 with non-RCVS). The RCVS–TCH score (range: 0–12) contained four predictors: recurrent TCHs, female sex, triggering factor for TCH (single or multi) and blood pressure surge. The C-index of RCVS–TCH score was 0.929 (95% CI = 0.874–0.984). The RCVS–TCH score ≥ 7 had a sensitivity of 80% and a specificity of 97% in discriminating RCVS from non-RCVS. In the validation set, RCVS–TCH score showed a C-index of 0.861 (95% CI = 0.815–0.908). In our study, the RCVS–TCH showed good performance, which may aid the diagnosis of RCVS among patients with TCH.
- 8 April 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-8
Open AccessRCVS–TCH score can predict reversible cerebral vasoconstriction syndrome in patients with thunderclap headache
Reversible cerebral vasoconstriction syndrome (RCVS) is one of the most important differential diagnosis in patients with thunderclap headache (TCH). We aimed to develop a new scoring system for RCVS in patients with TCH. We retrospectively analyzed 72 patients enrolled in the prospective study of TCH conducted in 2015–2016 (derivation set). We identified possible predictors for the diagnosis of RCVS and constructed a prediction model (RCVS–TCH score) using the multivariable logistic regression model. Diagnostic performance was validated to an independent validation set from our headache registry. The derivation set comprised 41 patients with RCVS and 31 with non-RCVS, and the validation set included 253 patients with TCH (165 with RCVS and 88 with non-RCVS). The RCVS–TCH score (range: 0–12) contained four predictors: recurrent TCHs, female sex, triggering factor for TCH (single or multi) and blood pressure surge. The C-index of RCVS–TCH score was 0.929 (95% CI = 0.874–0.984). The RCVS–TCH score ≥ 7 had a sensitivity of 80% and a specificity of 97% in discriminating RCVS from non-RCVS. In the validation set, RCVS–TCH score showed a C-index of 0.861 (95% CI = 0.815–0.908). In our study, the RCVS–TCH showed good performance, which may aid the diagnosis of RCVS among patients with TCH.
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Clinical Neurology
- Vol. 17 (2) , 229-235
Smoking History and Clinical Features of Cluster Headache: Results from the Korean Cluster Headache Registry
Chung PW, et al. J Clin Neurol. 2021 Apr;17(2):229-235. https://doi.org/10.3988/jcn.2021.17.2.229
- 1 January 2021
- Published by XMLink in Journal of Clinical Neurology
- Vol. 17 (2) , 229-235
Open AccessSmoking History and Clinical Features of Cluster Headache: Results from the Korean Cluster Headache Registry
Chung PW, et al. J Clin Neurol. 2021 Apr;17(2):229-235. https://doi.org/10.3988/jcn.2021.17.2.229
- Open Access
- 30 June 2020
- Published by Korean Society of Neurosonology in Journal of Neurosonology and Neuroimaging
- Vol. 12 (1) , 26-32
Mechanisms Involved in Lacunar Infarction and Their Role in Early Neurological Deterioration
Emic strokes and causes significant morbidity. 1,2 Early neurological deterioration (END) can occur in 20-30% of patients with lacunar infarction during the first few days and lead to worse neurological outcomes. 3 The mechanisms of lacunar infarction are still un-Background: The mechanisms of lacunar infarction are still unclear and may be heterogenous. We aimed to investigate the presence of parent artery atheroma, cerebral vasodilatory function, and blood-brain barrier (BBB) breakdown and their role in the development of early neurological deterioration (END) in patients with acute lacunar infarction. Methods: Patients with acute lacunar infarction prospectively underwent transcranial Doppler breath-holding test, contrast-enhanced f luid-attenuated inversion recovery magnetic resonance imaging, and magnetic resonance angiography with/without high-resolution vessel wall imaging to determine the cerebral vasomotor reactivity to carbon dioxide (CO 2-CVR) of the symptomatic artery, BBB breakdown, and the presence of branch atheromatous disease in the parent artery, respectively, before the development of END. We compared the presence of each mechanism between patients who developed END and those without END and the role in predicting END between mechanisms. Results: Among the 41 patients included, three (7.3%) experienced END. Reduced CO 2-CVR, branch atheromatous disease, and widespread BBB breakdown were observed in eight (19.5%), 10 (24.4%), and 11 patients (26.8%), respectively. Among these factors, CO 2-CVR was significantly lower in patients with END than in those without END (breath-holding index, 0.64 [interquartile range, 0.47-0.70] vs. 1.05 [0.81-1.33], p=0.028) and best predicted END (area under the curve=0.889; 95% confidence interval, 0.779-0.999; p<0.001). Conclusion: Cerebral vasodilatory dysfunction is associated with END in patients with acute lacunar infarction. Our study suggests that CO 2-CVR testing has a role in the risk stratification of lacunar infarction, and a confirmatory study is required in the future.
- 30 June 2020
- Published by Korean Society of Neurosonology in Journal of Neurosonology and Neuroimaging
- Vol. 12 (1) , 26-32
Open AccessMechanisms Involved in Lacunar Infarction and Their Role in Early Neurological Deterioration
Emic strokes and causes significant morbidity. 1,2 Early neurological deterioration (END) can occur in 20-30% of patients with lacunar infarction during the first few days and lead to worse neurological outcomes. 3 The mechanisms of lacunar infarction are still un-Background: The mechanisms of lacunar infarction are still unclear and may be heterogenous. We aimed to investigate the presence of parent artery atheroma, cerebral vasodilatory function, and blood-brain barrier (BBB) breakdown and their role in the development of early neurological deterioration (END) in patients with acute lacunar infarction. Methods: Patients with acute lacunar infarction prospectively underwent transcranial Doppler breath-holding test, contrast-enhanced f luid-attenuated inversion recovery magnetic resonance imaging, and magnetic resonance angiography with/without high-resolution vessel wall imaging to determine the cerebral vasomotor reactivity to carbon dioxide (CO 2-CVR) of the symptomatic artery, BBB breakdown, and the presence of branch atheromatous disease in the parent artery, respectively, before the development of END. We compared the presence of each mechanism between patients who developed END and those without END and the role in predicting END between mechanisms. Results: Among the 41 patients included, three (7.3%) experienced END. Reduced CO 2-CVR, branch atheromatous disease, and widespread BBB breakdown were observed in eight (19.5%), 10 (24.4%), and 11 patients (26.8%), respectively. Among these factors, CO 2-CVR was significantly lower in patients with END than in those without END (breath-holding index, 0.64 [interquartile range, 0.47-0.70] vs. 1.05 [0.81-1.33], p=0.028) and best predicted END (area under the curve=0.889; 95% confidence interval, 0.779-0.999; p<0.001). Conclusion: Cerebral vasodilatory dysfunction is associated with END in patients with acute lacunar infarction. Our study suggests that CO 2-CVR testing has a role in the risk stratification of lacunar infarction, and a confirmatory study is required in the future.
- 1 May 2020
- Published by Wolters Kluwer Health in Stroke
- Vol. 51 (5) , 1451-1457
Temporal Profile of Blood-Brain Barrier Breakdown in Reversible Cerebral Vasoconstriction Syndrome
Background and Purpose—: Reversible cerebral vasoconstriction syndrome (RCVS) has a unique temporal course of vasoconstriction. Blood-brain barrier (BBB) breakdown is part of the pathophysiology of RCVS, but its temporal course is unknown. We aimed to investigate the temporal profile of BBB breakdown and relevant clinical profiles in a large sample size. Methods—: In this prospective observatory bicenter study, patients who underwent contrast-enhanced fluid-attenuated inversion recovery magnetic resonance imaging within 2 months from onset were included. The presence and extent of BBB breakdown were evaluated using contrast-enhanced fluid-attenuated inversion recovery magnetic resonance imaging. Contrast-enhanced fluid-attenuated inversion recovery magnetic resonance imaging data were analyzed using a semiautomated segmentation technique to quantitatively measure the area of Gadolinium leakage into cerebrospinal fluid space. The univariable and multivariable linear regressions were performed to investigate the independent effect of time from onset with adjustment for other covariates. Results—: In the 186 patients with angiogram-proven RCVS included in this analysis, BBB breakdown was observed in 52.6%, 56.8%, 30.3%, 40.0%, and 23.8% in the first, second, third, fourth, and ≥fifth week after onset. The extent of BBB breakdown peaked at first and second week, whereas the peak of vasoconstriction was observed at the third week after onset. Multivariable analysis showed the second week from onset (β, 3.35 [95% CI, 0.07–6.64]; P =0.046) and blood pressure surge (β, 3.84 [95% CI, 1.75–5.92]; P P for interaction=0.006). Conclusions—: Frequency and extent of BBB breakdown are more prominent during the early stage in patients with RCVS, with an earlier peak than that of vasoconstriction. The temporal course of BBB breakdown may provide a pathophysiologic background of the temporal course of neurological complications of RCVS.
- 1 May 2020
- Published by Wolters Kluwer Health in Stroke
- Vol. 51 (5) , 1451-1457
Temporal Profile of Blood-Brain Barrier Breakdown in Reversible Cerebral Vasoconstriction Syndrome
Background and Purpose—: Reversible cerebral vasoconstriction syndrome (RCVS) has a unique temporal course of vasoconstriction. Blood-brain barrier (BBB) breakdown is part of the pathophysiology of RCVS, but its temporal course is unknown. We aimed to investigate the temporal profile of BBB breakdown and relevant clinical profiles in a large sample size. Methods—: In this prospective observatory bicenter study, patients who underwent contrast-enhanced fluid-attenuated inversion recovery magnetic resonance imaging within 2 months from onset were included. The presence and extent of BBB breakdown were evaluated using contrast-enhanced fluid-attenuated inversion recovery magnetic resonance imaging. Contrast-enhanced fluid-attenuated inversion recovery magnetic resonance imaging data were analyzed using a semiautomated segmentation technique to quantitatively measure the area of Gadolinium leakage into cerebrospinal fluid space. The univariable and multivariable linear regressions were performed to investigate the independent effect of time from onset with adjustment for other covariates. Results—: In the 186 patients with angiogram-proven RCVS included in this analysis, BBB breakdown was observed in 52.6%, 56.8%, 30.3%, 40.0%, and 23.8% in the first, second, third, fourth, and ≥fifth week after onset. The extent of BBB breakdown peaked at first and second week, whereas the peak of vasoconstriction was observed at the third week after onset. Multivariable analysis showed the second week from onset (β, 3.35 [95% CI, 0.07–6.64]; P =0.046) and blood pressure surge (β, 3.84 [95% CI, 1.75–5.92]; P P for interaction=0.006). Conclusions—: Frequency and extent of BBB breakdown are more prominent during the early stage in patients with RCVS, with an earlier peak than that of vasoconstriction. The temporal course of BBB breakdown may provide a pathophysiologic background of the temporal course of neurological complications of RCVS.
- Open Access
- 1 January 2020
- Published by Korean Neurological Association in Journal of Clinical Neurology
- Vol. 16 (2) , 330-332
No Association of RNF213 Polymorphism with Reversible Cerebral Vasoconstriction Syndrome
Song J, et al. J Clin Neurol. 2020 Apr;16(2):330-332. https://doi.org/10.3988/jcn.2020.16.2.330
- 1 January 2020
- Published by Korean Neurological Association in Journal of Clinical Neurology
- Vol. 16 (2) , 330-332
Open AccessNo Association of RNF213 Polymorphism with Reversible Cerebral Vasoconstriction Syndrome
Song J, et al. J Clin Neurol. 2020 Apr;16(2):330-332. https://doi.org/10.3988/jcn.2020.16.2.330
- Open Access
- 1 January 2020
- Published by Korean Neurological Association in Journal of Clinical Neurology
- Vol. 16 (2) , 237-244
Effect of Sleep Quality on Headache-Related Impact in Primary Headache Disorders
Cho S, et al. J Clin Neurol. 2020 Apr;16(2):237-244. https://doi.org/10.3988/jcn.2020.16.2.237
- 1 January 2020
- Published by Korean Neurological Association in Journal of Clinical Neurology
- Vol. 16 (2) , 237-244
Open AccessEffect of Sleep Quality on Headache-Related Impact in Primary Headache Disorders
Cho S, et al. J Clin Neurol. 2020 Apr;16(2):237-244. https://doi.org/10.3988/jcn.2020.16.2.237
- Open Access
- 5 November 2019
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 8 (21) , e013215
Prevalence and Impact of Venous and Arterial Thromboembolism in Patients With Embolic Stroke of Undetermined Source With or Without Active Cancer
Background: An increased risk of acute ischemic stroke is recognized among patients with cancer. However, the mechanism behind cancer‐related stroke is unclear. In this study, we determined the presence of associated venous thromboembolism and arterial thromboembolism and their clinical impact on patients with cancer‐related stroke. Methods and Results: Patients with embolic stroke of undetermined source with or without cancer were evaluated for venous thromboembolism (deep vein thrombosis [ DVT ] and/or pulmonary embolism) and arterial thromboembolism by using Doppler sonography to determine the presence of lower‐extremity DVT and the microembolic signal of the symptomatic cerebral circulation, respectively. Infarct volume was determined by diffusion‐weighted magnetic resonance imaging. The multivariable linear regression and Cox proportional hazard analysis were used to investigate the effect of DVT and microembolic signal on infarct volume and 1‐year survival, respectively. Of 142 screened patients, 118 were included (37 with, 81 without cancer). Those with cancer had a higher prevalence of DVT or microembolic signal than did the noncancer group (62.2% versus 19.8%; P P =0.028). Presence of DVT (hazard ratio, 16.79; 95% CI, 2.05–137.75; P =0.009) and microembolic signal (hazard ratio, 8.16; 95% CI , 1.36–48.85; P =0.022) were independent predictors of poor 1‐year survival. Conclusions: Patients with cancer‐associated embolic stroke of undetermined source have an elevated risk of associated venous thromboembolism and arterial thromboembolism, both of which have a significant negative impact on 1‐year survival. The results of this study may enhance our understanding of cancer‐associated stroke and improve risk stratification of patients with this disease. Clinical Trial Registration: URL : https://www.clinicaltrials.gov/.Unique identifier: NCT 02212496
- 5 November 2019
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 8 (21) , e013215
Open AccessPrevalence and Impact of Venous and Arterial Thromboembolism in Patients With Embolic Stroke of Undetermined Source With or Without Active Cancer
Background: An increased risk of acute ischemic stroke is recognized among patients with cancer. However, the mechanism behind cancer‐related stroke is unclear. In this study, we determined the presence of associated venous thromboembolism and arterial thromboembolism and their clinical impact on patients with cancer‐related stroke. Methods and Results: Patients with embolic stroke of undetermined source with or without cancer were evaluated for venous thromboembolism (deep vein thrombosis [ DVT ] and/or pulmonary embolism) and arterial thromboembolism by using Doppler sonography to determine the presence of lower‐extremity DVT and the microembolic signal of the symptomatic cerebral circulation, respectively. Infarct volume was determined by diffusion‐weighted magnetic resonance imaging. The multivariable linear regression and Cox proportional hazard analysis were used to investigate the effect of DVT and microembolic signal on infarct volume and 1‐year survival, respectively. Of 142 screened patients, 118 were included (37 with, 81 without cancer). Those with cancer had a higher prevalence of DVT or microembolic signal than did the noncancer group (62.2% versus 19.8%; P P =0.028). Presence of DVT (hazard ratio, 16.79; 95% CI, 2.05–137.75; P =0.009) and microembolic signal (hazard ratio, 8.16; 95% CI , 1.36–48.85; P =0.022) were independent predictors of poor 1‐year survival. Conclusions: Patients with cancer‐associated embolic stroke of undetermined source have an elevated risk of associated venous thromboembolism and arterial thromboembolism, both of which have a significant negative impact on 1‐year survival. The results of this study may enhance our understanding of cancer‐associated stroke and improve risk stratification of patients with this disease. Clinical Trial Registration: URL : https://www.clinicaltrials.gov/.Unique identifier: NCT 02212496
- Open Access
- 18 June 2019
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 10, 644
Effect of Nimodipine Treatment on the Clinical Course of Reversible Cerebral Vasoconstriction Syndrome
Background: In reversible cerebral vasoconstriction syndrome (RCVS), nimodipine is currently used for the treatment, although no evidence is available to support its disease-modifying effect. In this prospective observational study, we investigated whether earlier nimodipine treatment can modify the clinical course of reversible cerebral vasoconstriction syndrome. Methods: We prospectively observed patients with angiogram-proven RCVS within 1 month after onset in the Samsung Medical Center between October 2015 and January 2018. Nimodipine was started in all patients immediately after diagnosis. Time from onset to the first nimodipine treatment was categorized as tertiles. We analyzed Kaplan-Meier curve and Cox proportional hazard model to test if the timing of nimodipine treatment can affect the clinical course of thunderclap headaches (TCHs) defined as the duration from onset to remission of thunderclap headaches. Results: In 82 patients included in this study, 71 (86.6%) patients showed remission of TCHs after starting nimodipine treatment. When categorized into earliest (p < 0.001). Univariable and multivariable Cox regression analyses also demonstrated an independent effect of earlier nimodipine treatment on earlier remission of TCHs (adjusted hazard ratio, 0.75 per 1-day delay in treatment; 95% CI, 0.693–0.802, p < 0.001). Conclusions: The clinical course of RCVS differed according to the timing of nimodipine treatment, suggesting the effect of earlier nimodipine treatment. In addition to preventing TCHs, beneficial effects of earlier nimodipine treatment on the progression of vasoconstriction and development of neurological complications should be investigated in future studies.
- 18 June 2019
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 10, 644
Open AccessEffect of Nimodipine Treatment on the Clinical Course of Reversible Cerebral Vasoconstriction Syndrome
Background: In reversible cerebral vasoconstriction syndrome (RCVS), nimodipine is currently used for the treatment, although no evidence is available to support its disease-modifying effect. In this prospective observational study, we investigated whether earlier nimodipine treatment can modify the clinical course of reversible cerebral vasoconstriction syndrome. Methods: We prospectively observed patients with angiogram-proven RCVS within 1 month after onset in the Samsung Medical Center between October 2015 and January 2018. Nimodipine was started in all patients immediately after diagnosis. Time from onset to the first nimodipine treatment was categorized as tertiles. We analyzed Kaplan-Meier curve and Cox proportional hazard model to test if the timing of nimodipine treatment can affect the clinical course of thunderclap headaches (TCHs) defined as the duration from onset to remission of thunderclap headaches. Results: In 82 patients included in this study, 71 (86.6%) patients showed remission of TCHs after starting nimodipine treatment. When categorized into earliest (p < 0.001). Univariable and multivariable Cox regression analyses also demonstrated an independent effect of earlier nimodipine treatment on earlier remission of TCHs (adjusted hazard ratio, 0.75 per 1-day delay in treatment; 95% CI, 0.693–0.802, p < 0.001). Conclusions: The clinical course of RCVS differed according to the timing of nimodipine treatment, suggesting the effect of earlier nimodipine treatment. In addition to preventing TCHs, beneficial effects of earlier nimodipine treatment on the progression of vasoconstriction and development of neurological complications should be investigated in future studies.